The treatment of HCV has undergone a dramatic evolution in the last several years. Whereas traditional interferon-based therapy for HCV was limited by poor efficacy and a heavy burden of side effects, interferon-free antiviral regimens are now available, offering new options for patients and altering the approach to this serious disease. The rapid pace of drug research, development, and approval requires frequent updates to treatment guidelines and leaves many clinicians wondering when, in whom, and how to manage chronic HCV infection.
In this CME program, we will discuss the latest findings in HCV through a review of salient presentations at the 2016 Digestive Disease Week meeting and the latest society recommendations for the appropriate use of antiviral therapy in patients with chronic HCV infection.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients infected with HCV or co-infected with HCV.
Upon completion of this activity, participants will be better able to do the following:
- Recognize and screen patients with high risk behaviors and those in disease prevalent birth cohorts
- Decrease time of initiation of treatment and improve long term treatment rates
- Explain the reported safety and efficacy of currently available treatments for HCV in patients co-infected with HIV
- List HCV drug combinations to avoid based on potential for drug-drug interactions
- Discuss clinical trial data and emerging therapies and agents
- Select appropriate new therapies and agents for optimal treatment of their patients
- Discuss with patients chronic and acute HCV infection’s natural history, impacts, and treatment
Jonathan S. Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier Jr., MD, Education Director and Professor of Internal Medicine
Interim Chair, Department of Clinical Sciences
Florida State University College of Medicine
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Jonathan S. Appelbaum, MD, FACP, AAHIVS|
Consultant/Advisor: Gilead; Janssen Global Services, LLC; Merck & Co., Inc.
Speaker's Bureau: Clinical Care Options, LLC
Non-faculty: Sherlyn Celone-Arnold; Joshua Kilbridge; Sandy Breslow; Alison Kemp; Leah Johnson and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.
Jointly provided by the Elsevier Office of Continuing Medical Education and Integrated Learning Partners, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integrated Learning Partners, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integrated Learning Partners, LLC., and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.